Best marker for screening for pre-eclampsia PAPPA or PLGF

Preeclampsia, a complex pathology, involves an imbalance of angiogenic factors. Our aim was to identify the best serum screening marker. For two years since 2018, a prospective comparative study was carried out on 356 patients, with serum PAPP-A and PLGF assays in the first trimester of pregnancy, to assess their predictive capacity for preeclampsia.Serum PAPP-A and PlGF concentrations were significantly lower in the group of women who had developed preeclampsia than in the control group. PlGF in MoM was 0.711 (vs. 1.147) (p<0.001), and PAPP-A was 0.863 MoM (vs. 1.165) (p<0.016). The sensitivity of PlGF was 62.5% and its specificity 87.5%, whereas the sensitivity of PAPP-A was 75% and its specificity 55.1%. The screening test combining the two markers had a better predictive value, with 88% sensitivity and 89% specificity.The PlGF assay appears interesting for early prediction of preeclampsia, but it is more effective to integrate it with the serum PAPP-A assay and clinical and biophysical data.